InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

ImpediMed Limited (ASX:IPD)

ALERT: Price-sensitive ASX Announcement for IPD
Current share price for IPD : $0.005 0.001 (25%)+
Announcement
Release
28 Jul 2026 8:31AM
Price at Release
$0.004
Full Release
download
Summary
ImpediMed Limited reported a strong performance in Q4 FY26, with revenues growing to $3.6 million and an increase in Annual Recurring Revenue to $14.4 million. The company sold 36 SOZO units in the US, contributing to the steady Core Business Total Contracted Value of $5.4 million. A successful capital raise of $15.3 million significantly bolstered their cash position, allowing for partial loan repayment and operational cost reductions. The company continues to expand its coverage in the US for Breast Cancer Related Lymphoedema, achieving 95% national coverage, and is actively pursuing opportunities in cancer survivorship and heart health markets.
Key Points
  • Revenue for Q4 FY26 was $3.6 million, a 3% increase from Q3 FY26.
  • Annual Recurring Revenue reached $14.4 million, marking a 2% rise compared to Q3 FY26.
  • SOZO® Core Business TCV was consistent at $5.4 million.
  • 36 SOZO units were sold in the US during the quarter.
  • The company raised $15.3 million through a capital raise.
  • Net operating cash outflows totaled $4.9 million.
  • Cash receipts for the quarter were $4.3 million.
  • The cash balance at the end of Q4 FY26 was $15.3 million.
  • Reimbursement for Breast Cancer Related Lymphoedema increased to cover 95% of the US population.
  • ImpediMed continues to focus on cancer survivorship and heart health markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.